Table 2.

Treatment engagement by study group

	CBT (n = 40)	TAU (n = 40)	P value*
No. of CBT sessions attended, mean (SD)	15.1 (3.5)
Completion rate of the full course of CBT sessions, n (%)	39 (97.5)
Length of CBT sessions, mean (SD), min	47.9 (4.5)
No. of psychiatrists visit, mean (SD)
Between baseline and 16 weeks (acute 16‐week phase)	12.0 (2.9)	10.9 (2.9)	0.10
Between 16 and 28 weeks (from end point to 3‐month follow‐up)	4.8 (3.4)	5.7 (3.3)	0.21
Between 28 and 40 weeks (from 3‐ to 6‐month follow‐up)	4.6 (2.6)	3.8 (2.8)	0.16
Between 40 and 64 weeks (from 6‐ to 12‐month follow‐up)	7.2 (4.3)	6.1 (5.1)	0.34
Medication
Antidepressants dose (DDD) at each time point, mean (SD), week
0 (baseline)	1.4 (0.7)	1.3 (0.7)	0.43
16	1.4 (0.9)	1.2 (0.9)	0.30
28 (3‐month follow‐up)	1.3 (0.9)	1.0 (0.9)	0.18
40 (6‐month follow‐up)	1.2 (1.0)	1.0 (0.8)	0.15
64 (12‐month follow‐up)	1.1 (1.0)	0.9 (1.0)	0.47
Anxiolytics/hypnotics dose (DDD) at each time point, mean (SD), week
0 (baseline)	1.7 (1.6)	1.4 (1.2)	0.27
16	1.6 (1.4)	1.2 (1.4)	0.26
28 (3‐month follow‐up)	1.6 (1.5)	1.0 (1.3)	0.06
40 (6‐month follow‐up)	1.6 (1.4)	1.0 (1.1)	0.03
64 (12‐month follow‐up)	1.3 (1.5)	1.0 (1.3)	0.32
Antipsychotics dose (DDD) at each time point, mean (SD), week
0 (baseline)	0.04 (0.12)	0.13 (0.27)	0.07
16	0.08 (0.24)	0.10 (0.24)	0.72
28 (3‐month follow‐up)	0.06 (0.20)	0.12 (0.27)	0.34
40 (6‐month follow‐up)	0.09 (0.26)	0.12 (0.28)	0.68
64 (12‐month follow‐up)	0.11 (0.28)	0.11 (0.28)	0.91
Mood stabilizer dose (DDD) at each time point, mean (SD), week
0 (baseline)	0.04 (0.15)	0.06 (0.18)	0.68
16	0.05 (0.15)	0.07 (0.22)	0.56
28 (3‐month follow‐up)	0.05 (0.14)	0.07 (0.16)	0.53
40 (6‐month follow‐up)	0.03 (0.12)	0.08 (0.16)	0.18
64 (12‐month follow‐up)	0.03 (0.14)	0.06 (0.16)	0.40

^* P values are for t‐test.

This is the intention‐to‐treat‐analysis.

CBT, cognitive‐behavioral therapy; DDD, defined daily dose; TAU, treatment as usual.